![Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ](https://www.cinj.org/sites/cinj/files/inline/images/CTchest1.jpg)
Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ
![Lung Cancer Survivors On Long Island Rave About Immunotherapy, Which Doctors Say Is Akin To A Cure For Some - CBS New York Lung Cancer Survivors On Long Island Rave About Immunotherapy, Which Doctors Say Is Akin To A Cure For Some - CBS New York](https://assets3.cbsnewsstatic.com/hub/i/r/2021/11/16/88a95fac-01bb-4ee6-a632-7d6a3352b5b3/thumbnail/1200x630/6d9f894edec91e36514cadd178f9805c/Lung-cancer-immunotherapy.jpg?v=42bbcea0e3eaab3fb7d470f54c86b0bd)
Lung Cancer Survivors On Long Island Rave About Immunotherapy, Which Doctors Say Is Akin To A Cure For Some - CBS New York
![Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ](https://www.cinj.org/sites/cinj/files/inline/images/HOS_Emblem-PC__Lung-Cancer-Surgery-2023-2024.jpg)
Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ
![Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet](https://www.thelancet.com/cms/attachment/1fe0761b-8416-4e5d-a567-a27d5649d2af/gr1_lrg.jpg)
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet
![First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health](https://www.englewoodhealth.org/wp-content/uploads/2018/08/spotlight_calypso.jpg)
First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health
Cooperman Barnabas Medical Center - As Lung Cancer Awareness Month comes to an end, we want to remind you that #LungCancer is the leading cause of cancer death in the United States.
![Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ Lung Cancer Treatment Program | Thoracic Oncology Program | Thoracic Cancer Program | Rutgers Cancer Institute of NJ](https://www.cinj.org/sites/cinj/files/news-release/thumb/AdobeStock_221990236.jpeg)